Currently out of the existing stock ratings of Kennen Mackay, 128 are a BUY (67.02%), 62 are a HOLD (32.46%), 1 are a SELL (0.52%).

Kennen Mackay

Work Performance Price Targets & Ratings Chart

Analyst Kennen Mackay, carries an average stock price target met ratio of 58.64% that have a potential upside of 22.71% achieved within 195 days. Previously, Kennen Mackay worked at RBC.

Kennen Mackay’s has documented 383 price targets and ratings displayed on 28 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on EXEL, Exelixis at 15-Oct-2024.

Wall Street Analyst Kennen Mackay

Analyst best performing recommendations are on ANAB (ANAPTYSBIO).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) at 4/4/2018. The price target of $86 was fulfilled within 2 days with a profit of $8.35 (8.85%) receiving and performance score of 44.25.

Average potential price target upside

of $67.98 (15.62%) on REGN (REGENERON PHARMACEUTICALS).
of $31.03 (25.11%) on ALXN (ALEXION PHARMACEUTICALS).
of $27.94 (16.36%) on AMGN (AMGEN).

ABEO Abeona Therapeutics AGIO Agios Pharm AIMT Aimmune Therapeutics AKBA Akebia Ther ALXN Alexion Pharmaceuticals AMGN Amgen ANAB AnaptysBio ARNA Arena Pharmaceuticals ATNX Athenex BMRN Biomarin Pharmaceutical CLVS Clovis Oncology EXEL Exelixis FPRX Five Prime Therapeutics GMAB Genmab AS IMGN ImmunoGen OBSV ObsEva SA ONCE Spark Therapeutics PBYI Puma Biotechnology PRTA Prothena plc REGN Regeneron Pharmaceuticals SGEN Seagen XLRN Acceleron Pharma ADCT ADC Therapeutics SA NUVB Nuvation Bio LIFE aTyr Pharma VIRX Viracta Therapeutics FGEN FibroGen RARE Ultragenyx

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)